OCRA is conducting a survey to gauge patient response to the expansion of telehealth in response to the pandemic. Since the onset of the COVID-19 pandemic, telehealth has been growing in popularity. Telehealth is the practice of caring for patients remotely when the provider and patient are not physically present with each other. Telehealth can refer to … Continued
As we count down to Ovarian Cancer Awareness Month and our virtual National Conference, there are so many ways to get involved … whether by learning more and connecting with others or raising awareness of the disease and vital funds for research. Read on to find out how you can be a voice, and a … Continued
Researchers at UT Southwestern have discovered a potential “Achilles’ heel” in ovarian cancer cells, and a new biomarker that may open up more avenues for targeted therapies. The study, published in the journal Cell, was led by W. Lee Kraus, PhD, Professor of Obstetrics and Gynecology and Pharmacology at UT Southwestern. Sridevi Challa, PhD, a … Continued
Sultry summer days can make anyone feel lazy and daydream of faraway places. But at OCRA, we’re working as hard as ever to fulfill our dream of a day when no one need fear an ovarian cancer diagnosis. Check out all that’s happening and discover ways that you can get involved. RESEARCH ADVOCACY PATIENT SUPPORT … Continued
Your Representative needs to hear from YOU. Please, urge your Representative to cosponsor Johanna’s Law today >> OCRA and the entire ovarian cancer community applaud the action taken on July 13, 2021 by Congresswoman Rosa DeLauro to reauthorize and expand Johanna’s Law. Since it was signed into law in 2007, Johanna’s Law has helped educate … Continued
A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations–and is effective even in tumors that have become resistant to PARP inhibitors. BRCA1 … Continued
Researchers from the University of Kansas School of Medicine conducted a study to capture the value and experience of giving and receiving peer support in the face of a gynecologic cancer diagnosis by interviewing Woman to Woman Mentors and Mentees from a newly created program at the University of Kansas Medical Center. As the report states, many … Continued
“It’s kind of like how the Apollo mission to the moon gave us Velcro.” Dr. David Chapel and his team are laying new groundwork in better understanding the origins of high-grade serous carcinoma, even if the exact applications are hard to see this early on. David, an OCRA grantee, speaks with great passion when he … Continued
Many people are surprised to learn that ovarian cancer is not one disease, but several distinct types and subtypes. Each type differs in who it typically affects, how it spreads, how it’s treated, and its prognosis. High grade serous ovarian cancer (HGSOC) is the most common, and is often the unspoken type we refer to … Continued
Before we head into the long holiday weekend, we wanted to share all the latest news and happenings. See below for updates in ovarian cancer research and advocacy, and discover new ways to get support and get involved. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
New research from The Wistar Institute and Peter MacCallum Cancer Center has uncovered a previously unknown checkpoint mechanism for gene expression, that may open up new avenues for transcription-based targeted cancer therapies in the future. This exciting study, published in the cancer journal Cell, was made possible in part by an OCRA research grant to … Continued
Flowers are blooming all around us, people are beginning to rediscover the things that matter most, and every day, OCRA grantees are making strides in understanding even more about ovarian cancer. Happy (almost!) May! RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
Get email updates about research news, action alerts, and ways to join the fight.
